What Is the Life Expectancy for Sacrum Cancer?

Life expectancy after a sacrum cancer diagnosis depends heavily on what type of tumor is involved. A slow-growing chordoma treated with surgery carries a median survival of roughly seven years, while a metastatic tumor that has spread to the sacrum from elsewhere in the body may carry a median survival closer to eleven months. These are broad figures, and individual prognosis can shift dramatically based on tumor grade, whether surgery achieves clean margins, whether the cancer has spread, and what treatments are available. Because the sacrum hosts such a diverse range of tumors, there is no single answer to this question.

Why “Sacrum Cancer” Is Not One Disease

The sacrum, the triangular bone at the base of the spine, can develop cancer in two fundamentally different ways. A primary tumor originates in the sacrum itself, arising from bone, cartilage, or remnant embryonic tissue. A secondary (metastatic) tumor arrives from somewhere else, most often the breast, prostate, or lung. Metastatic deposits in the sacrum are actually more common than primary sacral tumors, but they carry a very different prognosis because the cancer has already spread through the body.

1PubMed Central. Imaging features of primary and secondary malignant tumours of the sacrum

Among primary tumors, the most common is chordoma, a rare bone cancer that develops from leftover cells of the notochord (the embryonic structure that eventually becomes the spine). Chondrosarcoma (arising from cartilage) and Ewing sarcoma (a high-grade cancer most common in younger patients) also occur in this area, though less frequently. Sacral tumors in general account for about 7% of all spinal tumors and tend to grow silently for years before detection, often discovered incidentally during imaging for an unrelated complaint or a minor injury.

2PubMed Central. Clinical manifestations, classification, and surgical management of sacral tumors and the need for personalized approach to sacrectomy

Sacral Chordoma Survival

Chordoma is the tumor most people are asking about when they search for sacral cancer prognosis, and it has the deepest evidence base. A multicenter retrospective study found that the median overall survival for sacral chordoma patients was about 81 months, or just under seven years. Patients who had radical surgery fared better than those treated with radiation alone: three-year overall survival was 96% in the surgical group compared to roughly 89% in the radiation group.

3PubMed Central. Long-Term Outcomes of Patients Diagnosed With Sacral Chordoma in a Retrospective Multicenter Study

A systematic review and meta-analysis that pooled data from thirteen studies and over 360 patients found five-year overall survival rates around 81% for surgery alone and 83% for radiation alone, with ten-year survival of about 63% after surgery. Combined therapy (surgery plus radiation) yielded a five-year rate of about 82% but a lower ten-year rate of 48%.

4World Neurosurgery: X. Could recent advances improve the survival times and quality of life for sacral and mobile spine chordomas? A systematic review and meta-analysis

Those numbers may sound encouraging for a bone cancer, and in relative terms they are. Chordomas grow slowly, which gives treatment a wider window. But the challenge with chordoma is that it recurs stubbornly. Local recurrence occurred in more than half of surgically treated patients in one long-term series, at an average of about four years after the initial operation. Disease-specific survival dropped to 57% at ten years and 45% at fifteen years.

5The Bone & Joint Journal. Can local recurrence of a sacral chordoma be treated by further surgery?

One study looking specifically at the consequences of recurrence found that all patients with a local recurrence who died did so from metastatic disease that developed after the recurrence. Ten-year disease-specific survival was 44% in patients who had experienced a local recurrence, compared to 84% in those who had not.

6PubMed Central. Association between Patient Age and the Risk of Mortality Following Local Recurrence of a Sacral Chordoma

Ewing Sarcoma and Chondrosarcoma of the Pelvis and Sacrum

High-grade sarcomas behave very differently from chordomas. Ewing sarcoma of the pelvis (which includes the sacrum) carries markedly worse survival than Ewing sarcoma in other locations. The two-year, five-year, and ten-year overall survival rates were about 70%, 50%, and 42%, respectively, and these were significantly lower than Ewing sarcoma at any other anatomic site.

7PubMed. Ewing sarcoma of the pelvis: Clinical features and overall survival

Treatment for pelvic and sacral Ewing sarcoma typically involves chemotherapy, and whether to add surgery, radiation, or both is debated. One database study found that for patients with regional (extraosseous but nonmetastatic) disease, surgery was associated with improved disease-specific survival over radiation alone. For earlier-stage tumors confined within bone, the differences between local treatment approaches were not statistically clear.

8PubMed. Impact of local treatment modality on overall- and disease-specific survival for nonmetastatic pelvic and sacral Ewing sarcoma

Chondrosarcoma of the sacrum is rarer still, and the evidence is thinner. Among patients who already had metastatic pelvic chondrosarcoma at diagnosis, surgical removal of the primary tumor was linked to improved disease-specific survival.

9PubMed. Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis?

Sacral Metastases

When cancer spreads to the sacrum from another organ, the prognosis reflects the advanced stage of the original disease. One surgical series reported a median overall survival of about eleven months after treatment for sacral metastases. Among patients with renal cell carcinoma, those whose sacrum was the only site of metastatic disease survived longer (a median of sixteen months) than those with cancer in multiple locations (nine months).

10Journal of Neurosurgery: Spine. Surgical treatment of sacral metastases: indications and results

Another series looking at different surgical approaches for sacral metastases found median survival of about eighteen months with en bloc (whole-tumor) resection and about twelve months with subtotal resection. The twelve-month overall survival rate was 50% for en bloc and roughly 28% for subtotal resection, though the difference between approaches did not reach statistical significance.

11PubMed Central. Surgical Treatment of Sacral Metastatic Tumors

The goal of surgery for sacral metastases is often palliative: reducing pain, stabilizing the spine, preserving nerve function, and improving quality of life for the remaining months. In some cases, particularly solitary metastases from certain tumor types like renal cell or thyroid cancer, more aggressive resection may offer a longer survival window, but the decision depends on the patient’s overall disease burden and fitness for a major operation.

What Determines Whether Survival Falls on the Better or Worse End

Across nearly all sacral tumor types, two factors consistently predict outcome: the quality of surgical margins and tumor size. A large study of surgically treated sacral chordomas found that these were the only two significant predictors of long-term outcome.

12PubMed. Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers

Wide surgical margins, meaning the surgeon removed enough healthy tissue around the tumor that no cancer cells were left at the cut edge, are associated with better local control and a trend toward improved overall survival. Negative margins (termed R0 in surgical reports) were linked to significantly lower local recurrence rates compared to operations that left microscopic or visible tumor behind.

13PubMed Central. Impact of Surgical Margins and Adjuvant Radiotherapy on Local Recurrence and Survival in Sacral Chordoma 14PubMed Central. Surgical Margins and Local Control in Resection of Sacral Chordomas

This creates a difficult clinical tension. The sacrum is surrounded by and intertwined with nerves that control bladder, bowel, sexual function, and leg movement. Cutting wider margins often means sacrificing more of these nerves, which trades a better chance at cure for a more severe functional deficit. Higher sacrectomies (removing more of the sacrum, closer to the lumbar spine) are associated with worse lower limb motor function and lower physical and mental health scores compared to lower sacrectomies.

15PubMed. Quality of life and functional outcomes following pelvic exenteration and sacrectomy

A multi-institutional series looking at colorectal cancers invading the sacrum found that patients undergoing high sacrectomy had higher rates of new numbness and weakness compared to those with low sacrectomy, though the small sample sizes meant these differences did not reach statistical significance.

16Journal of Neurosurgery: Spine. Outcomes after en bloc resection with sacrectomy of advanced colorectal carcinomas that invade the sacrum

Particle Beam Radiation for Sacral Chordoma

Conventional radiation has limited effectiveness against chordoma because these tumors are relatively resistant to standard photon beams, and the sacrum sits close to the bowel and other sensitive structures that constrain how much dose you can deliver. Proton and carbon ion beams can deposit their energy more precisely, allowing higher doses to the tumor while sparing nearby tissue.

A phase II randomized trial comparing proton and carbon ion therapy for sacral chordoma reported two-year and four-year overall survival rates of 96% and 81%, with local progression-free survival of 84% at two years and 70% at four years. No significant difference was found between the two particle types.

17PubMed. Hypofractionated proton and carbon ion beam radiotherapy for sacrococcygeal chordoma (ISAC): An open label, randomized, stratified, phase II trial

An earlier study using particle therapy as definitive (primary) treatment for sacral chordoma reported three-year local control of 94%, overall survival of 83%, and progression-free survival of 68%.

18PubMed Central. Particle therapy using carbon ions or protons as a definitive therapy for patients with primary sacral chordoma

These results have made particle beam therapy an important option, either as a stand-alone treatment for patients who are not surgical candidates or as an adjunct after incomplete resection. Availability remains a practical limitation, since proton and carbon ion centers are still relatively scarce.

Targeted Therapies for Advanced or Recurrent Chordoma

Chordoma does not respond well to standard chemotherapy, which has pushed researchers toward molecular targeted drugs. A systematic review found that imatinib and erlotinib were the most frequently studied agents. For tumors expressing certain growth factor receptors (PDGFR or EGFR), these drugs achieved clinical benefit with tolerable side effects, though the responses are typically stabilization of disease rather than dramatic shrinkage.

19PubMed Central. Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review

A large European retrospective series of patients with advanced chordoma treated with targeted therapies reported a median progression-free survival of about six and a half months and median overall survival of roughly 30 months on first-line treatment. Second-line treatment showed a median progression-free survival of about ten months and overall survival of roughly 37 months, though these patients were likely a selected group fit enough to receive another line of therapy.

20PubMed Central. Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series

The honest assessment is that targeted therapies currently buy time rather than cure advanced chordoma. Research into the brachyury vaccine, a treatment aimed at a protein nearly universally expressed in chordoma cells, has shown early promise but remains experimental. For now, these drugs are mainly reserved for patients whose tumors cannot be fully resected or who have developed metastatic disease.

The Problem of Late Recurrence

One feature that makes sacral chordoma particularly tricky is its willingness to come back many years after apparently successful surgery. Most recurrences happen within the first five to ten years, but documented cases of recurrence at seventeen and nineteen years after en bloc resection show that these tumors can hide dormant tissue for remarkably long periods.

21PubMed. Late local recurrence, at 19 and 17 years, of sacral chordoma treated by en bloc resection

In the long-term series mentioned earlier, local recurrence-free survival dropped from 49% at five years to 37% at ten years and just 20% at fifteen years.

5The Bone & Joint Journal. Can local recurrence of a sacral chordoma be treated by further surgery?

This has practical implications for surveillance. Specialists increasingly recommend that sacral chordoma patients continue annual imaging for at least twenty years after initial treatment, rather than tapering off after the conventional five- or ten-year follow-up window. A recurrence caught early while still small has a better chance of being resectable than one discovered after it has grown large enough to cause new symptoms.

Complications, Functional Deficits, and Quality of Life

Survival statistics for sacral cancer only tell part of the story. The surgery itself is one of the most demanding procedures in orthopedic and neurosurgical oncology, and the functional cost can be significant. In one large-volume cancer center series, the perioperative complication rate after sacrectomy was about 39%, the thirty-day readmission rate was 16%, and more than half of patients were discharged to a facility rather than home.

The level of sacrectomy matters for daily life. Patients whose surgery involved a cut above the S2-S3 junction (high sacrectomy) had significantly worse lower limb motor function and reported lower physical and mental health scores compared to those with a lower-level resection.

15PubMed. Quality of life and functional outcomes following pelvic exenteration and sacrectomy

Common long-term effects of sacrectomy include bladder dysfunction (sometimes requiring self-catheterization), bowel changes, sexual dysfunction, and leg weakness or numbness. The extent of these problems depends on which sacral nerve roots are sacrificed. Sparing both S2 nerve roots generally preserves bladder function; losing them makes significant urinary problems likely. One study examining quality of life after sacrectomy for primary bone tumors found no significant differences in pre- and postoperative quality-of-life scores across various dimensions, though this may partly reflect adaptation over time and the relief of having the tumor removed.

22PubMed. Clinical results and quality of life after reconstruction following sacrectomy for primary bone malignancy

Why Where You Get Treated Can Matter

Sacral tumors are rare enough that most surgeons and oncology teams encounter only a handful over an entire career. This rarity means there is a meaningful gap in experience between general centers and specialized sarcoma or spinal oncology referral centers. Achieving clean surgical margins on a sacral chordoma requires a surgeon who understands the anatomy intimately and has done enough of these operations to navigate the balance between oncologic radicality and nerve preservation.

Though formal survival comparisons between high-volume and low-volume centers are limited for sacral tumors specifically, the pattern seen in other complex cancer surgeries, where outcomes improve with institutional experience, is widely assumed to apply here as well. Given that margin quality and tumor size are the strongest predictors of long-term survival, being treated at a center experienced in sacral tumor surgery is one of the more meaningful decisions a patient can influence.